Vitamin Shoppe, Inc (NYSE:VSI) had its price target reduced by Barclays PLC from $6.00 to $3.00 in a report published on Thursday. They currently have an equal weight rating on the specialty retailer’s stock.

A number of other equities analysts have also commented on the stock. Morgan Stanley cut their price target on shares of Vitamin Shoppe from $7.50 to $4.00 and set an equal weight rating on the stock in a report on Thursday. Zacks Investment Research lowered shares of Vitamin Shoppe from a hold rating to a sell rating in a report on Tuesday, November 7th. ValuEngine upgraded shares of Vitamin Shoppe from a hold rating to a buy rating in a report on Thursday, October 5th. Bank of America Corporation reiterated an underperform rating and set a $5.00 price target (down previously from $5.50) on shares of Vitamin Shoppe in a report on Wednesday, August 23rd. Finally, TheStreet lowered shares of Vitamin Shoppe from a c- rating to a d rating in a report on Wednesday, August 9th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. Vitamin Shoppe has an average rating of Hold and an average target price of $5.00.

Shares of Vitamin Shoppe (NYSE VSI) remained flat at $$3.50 during trading hours on Thursday. The company’s stock had a trading volume of 709,300 shares, compared to its average volume of 597,803. The company has a market cap of $83.92, a price-to-earnings ratio of 3.76 and a beta of 0.74. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.07 and a quick ratio of 0.34. Vitamin Shoppe has a twelve month low of $2.95 and a twelve month high of $26.60.

Vitamin Shoppe (NYSE:VSI) last issued its quarterly earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.20). The business had revenue of $288.20 million for the quarter, compared to analyst estimates of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. Vitamin Shoppe’s revenue for the quarter was down 8.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. equities research analysts anticipate that Vitamin Shoppe will post 0.53 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Barclays PLC Cuts Vitamin Shoppe, Inc (VSI) Price Target to $3.00” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/11/12/barclays-plc-cuts-vitamin-shoppe-inc-vsi-price-target-to-3-00.html.

In other news, Director John D. Bowlin bought 40,000 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the completion of the acquisition, the director now directly owns 56,028 shares in the company, valued at $308,154. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its holdings in Vitamin Shoppe by 0.8% in the second quarter. Arizona State Retirement System now owns 12,460 shares of the specialty retailer’s stock valued at $145,000 after buying an additional 100 shares during the period. Texas Permanent School Fund lifted its holdings in Vitamin Shoppe by 0.8% in the second quarter. Texas Permanent School Fund now owns 17,389 shares of the specialty retailer’s stock valued at $203,000 after buying an additional 145 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in Vitamin Shoppe by 2.1% in the second quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock valued at $108,000 after buying an additional 192 shares during the period. Capstone Asset Management Co. lifted its holdings in Vitamin Shoppe by 3.5% in the second quarter. Capstone Asset Management Co. now owns 14,040 shares of the specialty retailer’s stock valued at $164,000 after buying an additional 470 shares during the period. Finally, Thrivent Financial For Lutherans lifted its holdings in Vitamin Shoppe by 1.5% in the first quarter. Thrivent Financial For Lutherans now owns 37,070 shares of the specialty retailer’s stock valued at $747,000 after buying an additional 560 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.